LLY Lilly (Eli)
Intrinsic value$1,339.64
Price (at call)$1,115.70
Margin of safety
+20.1%
vs market (rating basis)
+93.7%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | 31.7% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 39.9% |
| Years to target margin | 5 |
| Sales-to-capital | 1.15 |
| Beta | 0.50 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 7.2% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 367.06B |
| PV of terminal value | 862.87B |
| Equity value | 1.19T |
| ÷ shares → per share | $1,339.64 |
News
score · 8 articles
- One State’s Battle to Stop People From Taking Unapproved Weight-Loss Drugs
- Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
- NVO Stock Logs Worst Week Since February As Novo Nordisk Rebrands To ‘Novo’ Amid Another Gloomy Year
- Novo ditches Nordisk from name as drugmaker attempts revival
- OPKO Health (OPK) Cashes In A Future Royalty Stream Early
- Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
- Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
- Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 104.91B | 31.7% | 49.4% | 41.53B | 21.88B | 19.65B | 18.34B |
| 2 | 134.87B | 28.6% | 47.0% | 50.82B | 25.96B | 24.86B | 21.65B |
| 3 | 169.16B | 25.4% | 44.6% | 60.53B | 29.71B | 30.81B | 25.05B |
| 4 | 206.86B | 22.3% | 42.2% | 70.08B | 32.68B | 37.40B | 28.38B |
| 5 | 246.50B | 19.2% | 39.9% | 78.82B | 34.35B | 44.47B | 31.48B |
| 6 | 286.00B | 16.0% | 39.9% | 91.45B | 34.24B | 57.21B | 37.80B |
| 7 | 322.89B | 12.9% | 39.9% | 103.24B | 31.96B | 71.28B | 43.96B |
| 8 | 354.41B | 9.8% | 39.9% | 113.32B | 27.32B | 86.00B | 49.50B |
| 9 | 377.92B | 6.6% | 39.9% | 120.84B | 20.37B | 100.47B | 53.96B |
| 10 | 391.15B | 3.5% | 39.9% | 125.07B | 11.46B | 113.61B | 56.95B |